StarRise Pharma and Pfizer Enter Exclusive Licensing Agreement with Up to US$2.3 Billion in Milestone Payments
2 day ago / Read about 0 minute
Author:小编   

Pfizer and StarRise Pharma have signed an exclusive licensing agreement under which Pfizer obtains exclusive rights to develop, manufacture, and commercialize three preclinical in vivo CAR-T programs for the treatment of autoimmune diseases outside Greater China. Pfizer may also apply StarRise Pharma's proprietary in vivo CAR-T technology in the fields of inflammatory and immune diseases and oncology, and has the option to secure exclusive licenses for candidate compounds from other collaborative research, as well as to expand the licensed territory to include Greater China. Under the terms of the agreement, StarRise Pharma will receive an upfront payment of US$330 million and is eligible for milestone payments of up to US$2.3 billion contingent on specific development and commercialization milestones, along with tiered royalties on net sales of approved products.